Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Advanta Immuno-Oncology Gene Expression Assay

Fluidigm has launched the Advanta Immuno-Oncology Gene Expression Assay, a research-use-only qPCR assay that enables interrogation of tumor immunobiology using Fluidigm's microfluidic technology. Designed for use with the Biomark HD system, the assay detects 170 gene expression markers involved in checkpoint therapeutic response from FFPE and fresh frozen tumor samples. The assay can analyze biomarkers across defined T cell subsets, immune regulation, immune cell fate, cytokines, chemokines, and more, and can enable translational researchers to accelerate the development of checkpoint immunotherapies and to identify predictive biomarker signatures for therapeutic response.

Fluidigm said that the product is available as a two-panel set. The first panel includes 91 key markers of tumor immune response that were previously shown in a multicenter international clinical trial to inform tumor progression and checkpoint therapeutic response. The second panel includes 74 additional immuno-oncology markers and 17 open assay inlets for additional customization. Both panels contain the same five reference genes and can be purchased and used together or separately.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.